KR20180104197A - 아베디테롤의 신규한 투약 형태 및 제형 - Google Patents

아베디테롤의 신규한 투약 형태 및 제형 Download PDF

Info

Publication number
KR20180104197A
KR20180104197A KR1020187026487A KR20187026487A KR20180104197A KR 20180104197 A KR20180104197 A KR 20180104197A KR 1020187026487 A KR1020187026487 A KR 1020187026487A KR 20187026487 A KR20187026487 A KR 20187026487A KR 20180104197 A KR20180104197 A KR 20180104197A
Authority
KR
South Korea
Prior art keywords
dose
pharmaceutically acceptable
range
free base
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187026487A
Other languages
English (en)
Korean (ko)
Inventor
루이스 산드리네 알라인
누네스 베아트리스 세오아네
미켈 세라 곤살로 데
Original Assignee
알미랄, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180104197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알미랄, 에스.에이. filed Critical 알미랄, 에스.에이.
Publication of KR20180104197A publication Critical patent/KR20180104197A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020187026487A 2012-05-31 2013-05-30 아베디테롤의 신규한 투약 형태 및 제형 Ceased KR20180104197A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
EP12382221.5 2012-05-31
US201261660003P 2012-06-15 2012-06-15
US61/660,003 2012-06-15
PCT/EP2013/061181 WO2013178742A1 (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033563A Division KR20150018526A (ko) 2012-05-31 2013-05-30 아베디테롤의 신규한 투약 형태 및 제형

Publications (1)

Publication Number Publication Date
KR20180104197A true KR20180104197A (ko) 2018-09-19

Family

ID=46317311

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187026487A Ceased KR20180104197A (ko) 2012-05-31 2013-05-30 아베디테롤의 신규한 투약 형태 및 제형
KR1020147033563A Ceased KR20150018526A (ko) 2012-05-31 2013-05-30 아베디테롤의 신규한 투약 형태 및 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147033563A Ceased KR20150018526A (ko) 2012-05-31 2013-05-30 아베디테롤의 신규한 투약 형태 및 제형

Country Status (29)

Country Link
US (2) US20150140099A1 (enExample)
EP (2) EP2668941A1 (enExample)
JP (1) JP6272836B2 (enExample)
KR (2) KR20180104197A (enExample)
CN (1) CN104394852A (enExample)
AR (1) AR091233A1 (enExample)
AU (1) AU2013269565B2 (enExample)
BR (1) BR112014029735A2 (enExample)
CA (1) CA2871358C (enExample)
CL (1) CL2014003286A1 (enExample)
CO (1) CO7141434A2 (enExample)
CR (1) CR20140540A (enExample)
DO (1) DOP2014000271A (enExample)
EA (1) EA201401354A1 (enExample)
EC (1) ECSP14028814A (enExample)
HK (1) HK1203149A1 (enExample)
IL (1) IL235831B (enExample)
IN (1) IN2014DN08672A (enExample)
MX (1) MX2014014350A (enExample)
MY (1) MY184654A (enExample)
NI (1) NI201400139A (enExample)
NZ (1) NZ701261A (enExample)
PE (1) PE20150171A1 (enExample)
PH (1) PH12014502662A1 (enExample)
SG (3) SG10201609119VA (enExample)
TW (1) TWI610690B (enExample)
UY (1) UY34838A (enExample)
WO (1) WO2013178742A1 (enExample)
ZA (1) ZA201407405B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2015193631A1 (en) * 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
EP3784322B1 (en) 2018-05-22 2023-11-22 C. R. Bard, Inc. Catheterization system and methods for use thereof
WO2020033752A1 (en) 2018-08-10 2020-02-13 C. R. Bard, Inc. Automated urine-output-measurement systems and methods thereof
US12083261B2 (en) 2020-06-05 2024-09-10 C. R. Bard, Inc. Automated fluid output monitoring
US12055249B2 (en) 2020-07-21 2024-08-06 C. R. Bard, Inc. Automatic fluid flow system with retractable connection
US12408853B2 (en) 2020-12-17 2025-09-09 C. R. Bard, Inc. Smart bag to measure urine output via catheter
US12364423B2 (en) 2020-12-21 2025-07-22 C. R. Bard, Inc. Automated urinary output-measuring systems and methods
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system
US12246146B2 (en) 2020-12-23 2025-03-11 C. R. Bard, Inc. Automated weight based fluid output monitoring system
US12446813B2 (en) 2021-08-23 2025-10-21 C. R. Bard, Inc. Automated urine output system for attachment to hospital bed
WO2025151671A1 (en) * 2024-01-12 2025-07-17 Texas Tech University System Compositions and methods for treating diet-induced obesity and associated metabolic disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE209938T1 (de) 1990-09-26 2001-12-15 Pharmachemie Bv Wirbelkammer-pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
UA27961C2 (uk) 1992-12-18 2000-10-16 Шерінг Корпорейшн Інгалятор для порошкових ліків
AU719449B2 (en) 1995-06-21 2000-05-11 Astrazeneca Ab Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005030220A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Also Published As

Publication number Publication date
CA2871358C (en) 2020-09-29
PH12014502662A1 (en) 2015-02-02
BR112014029735A2 (pt) 2017-06-27
PE20150171A1 (es) 2015-01-31
HK1203149A1 (en) 2015-10-23
NI201400139A (es) 2015-12-10
DOP2014000271A (es) 2015-02-27
KR20150018526A (ko) 2015-02-23
CA2871358A1 (en) 2013-12-05
WO2013178742A1 (en) 2013-12-05
CL2014003286A1 (es) 2015-02-20
IL235831A0 (en) 2015-01-29
EA201401354A1 (ru) 2015-05-29
CO7141434A2 (es) 2014-12-12
SG10201913424SA (en) 2020-03-30
AU2013269565B2 (en) 2017-07-20
ECSP14028814A (es) 2015-12-31
EP2854771A1 (en) 2015-04-08
EP2668941A1 (en) 2013-12-04
SG11201407110QA (en) 2014-12-30
CN104394852A (zh) 2015-03-04
ZA201407405B (en) 2015-11-25
IN2014DN08672A (enExample) 2015-05-22
JP2015519356A (ja) 2015-07-09
AU2013269565A1 (en) 2014-10-30
TWI610690B (zh) 2018-01-11
IL235831B (en) 2020-09-30
UY34838A (es) 2014-03-31
SG10201609119VA (en) 2016-12-29
US20150140099A1 (en) 2015-05-21
NZ701261A (en) 2016-08-26
CR20140540A (es) 2015-01-16
MX2014014350A (es) 2015-03-03
MY184654A (en) 2021-04-14
JP6272836B2 (ja) 2018-01-31
TW201347789A (zh) 2013-12-01
AR091233A1 (es) 2015-01-21
US20160303108A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AU2013269565B2 (en) Novel dosage form and formulation of abediterol
JP5289306B2 (ja) 加圧式定量噴霧吸入器用の薬学的溶液製剤
RU2608713C2 (ru) Новая доза и препаративная форма
KR20150120391A (ko) 마바 화합물 및 코르티코스테로이드를 포함하는 조합물
EP2398473B1 (en) 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function
KR20150010757A (ko) 신규한 투약량 및 제형
CN107205936A (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
TW201031409A (en) Novel methods
EA030015B1 (ru) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ ГЕМИНАПАДИЗИЛАТА 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНИЛЭТОКСИ)ГЕКСИЛ]АМИНО}-1-(R)-ГИДРОКСИЭТИЛ)-8-ГИДРОКСИХИНОЛИН-2(1H)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
WO2011098799A2 (en) Respiratory disease treatment
US20100210611A1 (en) Combination therapy
JP2004500432A (ja) モメタゾンとサルメテロールを含む組合せ医薬
JP6346618B2 (ja) アクリジニウムの新規用途
JP7712916B2 (ja) 吸入用乾燥粉末製剤のための新規担体粒子
KR20170086489A (ko) 부데소니드 및 포르모테롤을 함유하는 약학 조성물
WO2015091287A1 (en) Dosage formulation comprising salmeterol and fluticasone propionate
HK1159990B (en) 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180912

Application number text: 1020147033563

Filing date: 20141128

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190318

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I